🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Related News

WhiteHat Jr founder Karan Bajaj raises $16 Mn for new startup Complement1

EntrackrEntrackr · 2m ago
WhiteHat Jr founder Karan Bajaj raises $16 Mn for new startup Complement1
Medial

WhiteHat Jr founder Karan Bajaj raises $16 Mn for new startup Complement1 WhiteHat Jr was acquired by Byju’s for $300 million three years ago. At the time, its CEO Karan Bajaj went on to lead Byju’s Future School before leaving the company in August 2021. Karan Bajaj, the co-founder of Byju’s-owned WhiteHat Jr, has raised $16 million in seed funding for his new startup Complement1. The round was led by Owl Ventures and Blume Ventures, with participation from other undisclosed investors. Complement1 is a cancer care startup focusing on personalized lifestyle coaching in the United States. According to the company, it is emerging from stealth to launch the first tech-enabled, clinically validated lifestyle modification platform for cancer patients and high-risk individuals—delivering personalized, daily guidance and education through one-on-one dedicated CoActive Coaches. “Lifestyle change is one of the most powerful yet underused tools in cancer care,” said Karan Bajaj, CEO and co-founder of Complement 1. “Every oncologist will tell you patients need more support incorporating clinically recommended physical activity, nutrition and mind-body practices. We’ve cracked the code on daily engagement with personalized, compassionate coaching—helping patients make meaningful, lasting improvements during and beyond treatment.” With this fundraise, Complement 1 plans to scale up its coaching infrastructure and operations across the United States, advance its AI-driven personalization engine, and partner with cancer centers, health plans, and employers to bring the program to their cancer patients, high-risk individuals, and survivors. A part of this funding company will also go towards product development to enhance the digital user experience for both patients and coaches.

Tvaster Genkalp raises $1.25 Mn in pre-Series A round

EntrackrEntrackr · 3m ago
Tvaster Genkalp raises $1.25 Mn in pre-Series A round
Medial

Title: Tvaster Genkalp raises $1.25 Mn in pre-Series A round Healthtech startup Tvaster Genkalp has raised $1.25 million in its pre-Series A round led by Ideaspring Capital. Existing backers such as Invigo Softwares and liver transplant expert Prof. Mohamed Rela also joined the round. The proceeds will be used to help expand and market Episcreen™ Liver, a new blood test that can detect liver cancer early with 90% accuracy. This test offers a better option than the current standard, Alpha-Fetoprotein (AFP), which has only 50% sensitivity. Founded in 2021 by Dr. Srikar Raman and K. Sreedurgalakshmi, Tvaster is building high-accuracy, non-invasive tests for cancer. It aims to improve early detection and save lives, especially for liver cancer, which affects over 900,000 people globally every year. Tvaster has tested Episcreen™ Liver on over 600 patients and plans to partner with top diagnostic labs for wider access. The firm is also working on tests for bile duct cancer and childhood liver cancer treatment resistance. It recently won the ILTS Young Researcher Award and received a BIRAC BIG Grant for its work in cancer diagnostics.

Biotech startup Exsure raises seed round led by Unicorn India Ventures

EntrackrEntrackr · 5m ago
Biotech startup Exsure raises seed round led by Unicorn India Ventures
Medial

Biotech startup Exsure has raised Rs 3 crore in a seed round led by Unicorn India Ventures. The fresh funds will be used to complete the non-clinical study of its exosome-based drug delivery platform, support its global expansion plans with in-house manufactured R&D products, and promote its offerings, including Exosure, Leucosure, PlantExosure, and Dr. Berries, the company said in a press release. Co-founded in 2021 by Swastika Paul and Abhishek Dutta, Exsure is a biotech startup focused on reducing the side effects and toxicity of anti-cancer drugs through its patented exosomal drug-delivery platform that targets both cancer and cancer stem cells. With its cutting-edge technology, the company aims to minimize the toxic effects of chemotherapy and reduce the likelihood of cancer relapse, thereby improving the quality of life for cancer patients. Over the past 12 months, Exsure has initiated a non-clinical study in India in collaboration with a CRO and completed preclinical studies using its patented technology. The company has launched its first in-house manufactured products and gained collaborators and partners across India for its products and services. According to market research, the Indian biotechnology industry is expected to reach $150 billion by 2025 and has the potential to grow to $270–300 billion by 2030. The Bhubaneswar-based company reported fivefold growth in the last fiscal year and is on track to service more than 50 clients this year with its R&D products, including Exosure (a 3-in-1 exosome isolation reagent), Leucosure (a PBMC isolation reagent), and PlantExosure (India’s first plant exosome isolation reagent). Additionally, the company has been selected for the OIST Innovation Accelerator Program in Japan to support its business expansion and conduct clinical trials.

ErlySign raises $1.8 Mn in pre-Series A round from Ashish Kacholia

EntrackrEntrackr · 6m ago
ErlySign raises $1.8 Mn in pre-Series A round from Ashish Kacholia
Medial

ErlySign raises $1.8 Mn in pre-Series A round from Ashish Kacholia Healthtech startup ErlySign has raised Rs 16 crore ($1.8 million) in its pre-Series A round from Ashish Kacholia. The proceeds will be used in clinical trials, securing CDSCO (Central Drugs Standard Control Organisation) approvals, and bringing ErlySign’s oral cancer detection kit to market. Founded in 2019 by Shubhendra Singh Thakur and Deovrat Begde, ErlySign develops solutions for early detection of oral cancer. The startup also claims to offer India’s first salivary biomarker-based test which can identify pre-cancerous conditions much before visible symptoms emerge. Looking ahead, ErlySign plans to use CRISPR miRNA-based testing technology to detect multiple types of cancer using the same saliva sample within 15–20 minutes.

Download the medial app to read full posts, comements and news.